PRONEC
Pronec Ltd seeks to develop a new class of cancer therapy that causes tumours to simply die, using proprietary peptides. The Company has identified a lead candidate molecule that causes necrosis of a wide range of tumour cell lines in culture, but does not affect normal cell lines. Cancer cell necrosis refers to death of cancer cells within a tumour. This new class of compounds is protected by GB and international patent applications.
PRONEC
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
Alderley Park, Cheshire, United Kingdom
Country:
United Kingdom
Status:
Active
Total Funding:
50 K GBP
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Nanobacterie
Nanobacterie is a start-up developing cancer treatment.
Oncotelic
Oncotelic is a cancer immunotherapy company
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
ViGeneron
ViGeneron is a gene therapy company.
Current Employees Featured
Founder
Investors List
Deepbridge Capital
Deepbridge Capital investment in Seed Round - Pronec
GM&C Life Sciences Fund
GM&C Life Sciences Fund investment in Seed Round - Pronec